Abstract
Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in HF. Although several trials investigated statins treatment effects on HF in general, some evidence exists about the role that these drugs can have in the progression of the disease in the specific category of HF patients affected by MetS. In this review the possible positive effects of the statins treatment in this specific subset of patients are discussed.
Keywords: Congestive heart failure, metabolic syndrome, statins
Current Pharmaceutical Design
Title: The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Volume: 14 Issue: 25
Author(s): Giovanni Fazio, Gisella Rita Amoroso, Giuseppe Barbaro, Giuseppina Novo and Salvatore Novo
Affiliation:
Keywords: Congestive heart failure, metabolic syndrome, statins
Abstract: Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in HF. Although several trials investigated statins treatment effects on HF in general, some evidence exists about the role that these drugs can have in the progression of the disease in the specific category of HF patients affected by MetS. In this review the possible positive effects of the statins treatment in this specific subset of patients are discussed.
Export Options
About this article
Cite this article as:
Fazio Giovanni, Amoroso Rita Gisella, Barbaro Giuseppe, Novo Giuseppina and Novo Salvatore, The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071218
DOI https://dx.doi.org/10.2174/138161208786071218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Recurrent Episodes of Pericardial Effusion as Isolated Manifestation of Tuberculosis: Case Report
Current Medical Imaging Lifestyle Interventions for Cardiovascular Risk Reduction in Women with Breast Cancer
Current Cardiology Reviews An Update on Clinical and Pharmacological Aspects of Drug-Eluting Stents
Cardiovascular & Hematological Disorders-Drug Targets Strategic Leukofiltration in Cardiac Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions
Current Pharmaceutical Design The Clinical Evaluation of Chronic Cough
Current Respiratory Medicine Reviews The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure
Current Medicinal Chemistry Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Current Medicinal Chemistry The Implications of Human Stem Cell Differentiation to Endothelial Cell Via Fluid Shear Stress in Cardiovascular Regenerative Medicine: A Review
Current Pharmaceutical Design